Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
APT Pharmaceuticals
Burlingame, California, United Statesaptbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
APT Pharmaceuticals developed inhaled cyclosporine for inflammatory diseases and transplantation. Its lead program, Pulminiq, advanced to a pivotal Phase III trial for prevention of lung transplant rejection. The company also pursued a novel cardioprotectant and other specialty drug projects targeting significant unmet medical needs. No recent clinical results are publicly available; most information dates from the late 2000s.
- Therapeutic areas
- ImmunologyCardiovascular
- Modalities
- Inhaled therapeuticsSmall molecules (e.g., cyclosporine)
- Industry
- Biotech
02
Partnerships
No major pharmaceutical partnerships disclosed; primary relationships are with venture capital investors.
Beyond the preview
Go deeper on APT Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APT Pharmaceuticals.